BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
BioMark Diagnostics (OTCQB: BMKDF), a liquid biopsy test developer, has completed a strategic laboratory equipment leasing agreement that doubles its testing capacity in Quebec. This expansion supports the upcoming commercial launch of its metabolomic-based lung cancer diagnostic assay and enhances the company's ability to provide advanced diagnostic analytical molecular services.
The upgraded facility will serve as a certified and accredited laboratory, enabling broad deployment through clinical partnerships, centralized testing services, and expanded contract research programs. The expansion positions BioMark to meet increasing global demand for non-invasive liquid biopsy diagnostics and supports research collaborations with healthcare institutions and pharmaceutical companies.
BioMark Diagnostics (OTCQB: BMKDF), sviluppatore di test di biopsia liquida, ha completato un accordo strategico di leasing di attrezzature di laboratorio che raddoppia la sua capacit脿 di test in Quebec. Questa espansione supporta il prossimo lancio commerciale del suo test diagnostico del cancro ai polmoni basato sul metabolomica e migliora la capacit脿 dell'azienda di offrire servizi avanzati di analisi molecolare diagnostica.
La struttura potenziata funger脿 da laboratorio certificato e accreditato, consentendo una vasta diffusione tramite partnership cliniche, servizi di test centralizzati e programmi di ricerca a contratto ampliati. L'espansione posiziona BioMark per soddisfare la crescente domanda globale di diagnostica non invasiva tramite biopsia liquida e supporta collaborazioni di ricerca con istituzioni sanitarie e aziende farmaceutiche.
BioMark Diagnostics (OTCQB: BMKDF), desarrollador de pruebas de biopsia l铆quida, ha completado un acuerdo estrat茅gico de arrendamiento de equipos de laboratorio que duplica su capacidad de pruebas en Quebec. Esta expansi贸n respalda el pr贸ximo lanzamiento comercial de su ensayo diagn贸stico de c谩ncer de pulm贸n basado en metabol贸mica y mejora la capacidad de la empresa para ofrecer servicios avanzados de an谩lisis molecular diagn贸stico.
La instalaci贸n mejorada funcionar谩 como un laboratorio certificado y acreditado, permitiendo una amplia implementaci贸n a trav茅s de asociaciones cl铆nicas, servicios de pruebas centralizados y programas ampliados de investigaci贸n por contrato. La expansi贸n posiciona a BioMark para satisfacer la creciente demanda global de diagn贸sticos no invasivos de biopsia l铆quida y apoya colaboraciones de investigaci贸n con instituciones de salud y compa帽铆as farmac茅uticas.
BioMark Diagnostics (OTCQB: BMKDF)電� 鞎§泊 靸濌瞼 瓴�靷� 臧滊皽鞐呾泊搿滌劀, 韤橂病鞐愳劀 瓴�靷� 鞖╇焿鞚� 霊� 氚半 電橂Μ電� 鞝勲灥鞝� 鞁ろ棙鞁� 鞛ル箘 鞛勲寑 瓿勳暯鞚� 鞕勲頄堨姷雼堧嫟. 鞚措矆 頇曥灔鞚� 雽�靷泊 旮半皹 韽愳晹 歆勲嫧 瓴�靷� 靸侅梾 於滌嫓毳� 歆�鞗愴晿氅�, 須岇偓鞚� 瓿犼笁 歆勲嫧 攵勳瀽 攵勳劃 靹滊箘鞀� 鞝滉车 電ル牓鞚� 頄レ儊鞁滍偟雼堧嫟.
鞐呹犯霠堨澊霌滊悳 鞁滌劋鞚� 鞚胳 氚� 瓿奠澑霅� 鞁ろ棙鞁�搿滌劀 旮半姤頃橃棳 鞛勳儊 韺岉姼雱堨嫮, 欷戩暀 歆戩鞁� 瓴�靷� 靹滊箘鞀�, 頇曤寑霅� 瓿勳暯 鞐瓣惮 頂勲攴鸽灗鞚� 韱淀暣 甏戨矓鞙勴暅 氚绊彫臧� 臧�電ロ暣歆戨媹雼�. 鞚措矆 頇曥灔鞚� BioMark臧� 牍勳龚鞀奠爜 鞎§泊 靸濌瞼 歆勲嫧鞐� 雽�頃� 鞝� 靹戈硠鞝侅澑 靾橃殧 歃濌皜鞐� 雽�鞚戫晿瓿�, 鞚橂 旮瓣磤 氚� 鞝滌暯靷檧鞚� 鞐瓣惮 順戨牓鞚� 歆�鞗愴晿電� 雿� 旮办棳頃╇媹雼�.
BioMark Diagnostics (OTCQB : BMKDF), d茅veloppeur de tests de biopsie liquide, a conclu un accord strat茅gique de location d鈥櫭﹒uipements de laboratoire qui double sa capacit茅 de test au Qu茅bec. Cette expansion soutient le lancement commercial prochain de son test diagnostique du cancer du poumon bas茅 sur la m茅tabolomique et am茅liore la capacit茅 de l'entreprise 脿 fournir des services analytiques mol茅culaires diagnostiques avanc茅s.
Les installations am茅lior茅es serviront de laboratoire certifi茅 et accr茅dit茅, permettant un d茅ploiement 茅tendu via des partenariats cliniques, des services de tests centralis茅s et des programmes de recherche sous contrat 茅largis. Cette expansion positionne BioMark pour r茅pondre 脿 la demande mondiale croissante en diagnostics non invasifs par biopsie liquide et soutient les collaborations de recherche avec des institutions de sant茅 et des entreprises pharmaceutiques.
BioMark Diagnostics (OTCQB: BMKDF), ein Entwickler von Fl眉ssigbiopsie-Tests, hat eine strategische Vereinbarung zum Leasing von Laborausr眉stung abgeschlossen, die seine Testkapazit盲t in Quebec verdoppelt. Diese Erweiterung unterst眉tzt die bevorstehende kommerzielle Einf眉hrung seines metabolombasierten Lungenkrebs-Diagnosetests und verbessert die F盲higkeit des Unternehmens, fortschrittliche diagnostische molekulare Analysedienste anzubieten.
Die aufger眉stete Einrichtung wird als zertifiziertes und akkreditiertes Labor dienen, was eine breite Anwendung durch klinische Partnerschaften, zentralisierte Testdienste und erweiterte Vertragsforschungsprogramme erm枚glicht. Die Expansion positioniert BioMark, um der steigenden globalen Nachfrage nach nicht-invasiven Fl眉ssigbiopsie-Diagnostika gerecht zu werden und unterst眉tzt Forschungskooperationen mit Gesundheitseinrichtungen und Pharmaunternehmen.
- Strategic equipment leasing agreement doubles testing capacity
- Positions for commercial launch of lung cancer diagnostic assay
- Expands capabilities for international pharmaceutical and biotech partnerships
- Enhanced platform for clinical validation studies and regulatory filings
- Facilitates deployment of multiple new assays
- Laboratory certification and accreditation still pending
- Significant operational costs from equipment leasing agreement
Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for the imminent commercial launch of its lung cancer assay. This critical advancement in its operational capabilities solidifies the expansion of its diagnostic and research services and positions the Company as a central hub for innovation, high-throughput diagnostics, and collaborative ventures.
Accelerating Commercialization and Market Entry for Life-Saving Diagnostics
The newly acquired state-of-the-art laboratory equipment is aligned with BioMark's commercialization strategy. This enhanced capacity directly addresses the escalating global demand for non-invasive liquid biopsy diagnostics and, crucially, prepares the Company for the widespread clinical deployment of its metabolomic-based lung cancer diagnostic assay. The expansion also facilitates the provision of advanced diagnostic analytical molecular services to international clients and significantly expands its research capabilities to accommodate the growing needs of metabolomics from pharmaceutical and biotechnology companies. Furthermore, this initiative supports the accelerated rollout of multiple new assays, aligning with the company's laboratory certification and accreditation roadmap.
"Our enhanced laboratory capacity underscores BioMark's unwavering commitment to clinical excellence, innovation, and accessibility," stated Jean-Francois Haince, CSO and GM of BioMark Diagnostic Solutions. "Once certified, this laboratory will serve as a pivotal engine for commercialization, revenue generation, strategic partnerships, and the widespread clinical deployment of our metabolomic-based diagnostic assays."
Creating a Platform for Scalable Growth and Strategic Value
This strategic laboratory upgrade aligns with BioMark's vision to establish an agile, clinically robust platform capable of supporting research on advanced cancer. It will also facilitate ongoing clinical research collaborations with global healthcare institutions and pharmaceutical companies, while streamlining regulatory filings and clinical validation studies for new indications and expansion into international markets. BioMark's forthcoming certified and accredited laboratory will be instrumental in enabling a broad deployment strategy through robust clinical partnerships, centralized testing services, and expanded contract research programs.
"Our team remains intensely focused on achieving key milestones and enhancing long-term shareholder value," added Rashid Ahmed Bux, President & CEO of BioMark. "This accomplishment strategically positions BioMark at a significant advantage within the diagnostic arena, marking a critical enabler as we continue to scale our AI-enhanced assays and foster collaborations across the entire cancer care spectrum. We are now well-equipped to meet the anticipated demand for our innovative solutions and drive significant growth."
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website and the CSE website .
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: [email protected]
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved of the content of this press release.
To view the source version of this press release, please visit
FAQ
What is the significance of BioMark's (BMKDF) laboratory expansion in Quebec?
How will the new laboratory equipment affect BioMark's (BMKDF) operations?
What are the main benefits of BioMark's (BMKDF) laboratory expansion for cancer diagnostics?
When will BioMark's (BMKDF) expanded laboratory be fully operational?
How does the laboratory expansion align with BioMark's (BMKDF) growth strategy?
